{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"This characteristic will be included in Cox models.","groups":[{"description":"Patients receive placebo PO twice daily in week 1 and then once daily in weeks 2-11. Patients also receive cisplatin IV over 3 hours once in weeks 2, 5, and 8 and undergo radiotherapy 5 days a week in weeks 2-8.\n\nplacebo: Given PO\n\ncisplatin: Given IV\n\nradiation therapy: Undergo radiotherapy\n\nquality-of-life assessment: Ancillary studies","id":"OG000","title":"Arm I (Placebo, Cisplatin, and Radiotherapy)"},{"description":"Patients receive selenomethionine PO twice daily in week 1 and then once daily in weeks 2-11. Patients also receive cisplatin and undergo radiotherapy as in arm I.\n\nselenomethionine: Given PO\n\ncisplatin: Given IV\n\nradiation therapy: Undergo radiotherapy\n\nquality-of-life assessment: Ancillary studies","id":"OG001","title":"Arm II (Selenomethionine, Cisplatin, and Radiotherapy)"}],"populationDescription":"Due to the study's early termination and inadequate number of patients, no patients were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to 8 weeks","title":"CRT Dose Delivery","type":"SECONDARY"}